Accessibility Menu

Cassava Sciences(NASDAQ) SAVAW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-99%
5 YearN/A
1 YearN/A
1 Month-99%
$0.00
+0.00%
+0.00Today
Cassava Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.032024-05-02
Cassava Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-90.33%USD 0.302024-04-25
1 month-99.18%USD 3.562024-04-02
3 month-99.61%USD 7.352024-02-02
Since inception-99.05%USD 3.062024-01-04

Cassava Sciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

SAVAW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cassava Sciences

Cassava Sciences, Inc. is a biotechnology firm focused on developing therapies for neurodegenerative disorders. The company is advancing its lead therapeutic asset, simufilam, and a diagnostic tool, SavaDx, aimed at early detection of Alzheimer's disease.

Products and Services
  • Simufilam, a small molecule drug for neurodegenerative disorders
  • SavaDx, a blood-based diagnostic tool for Alzheimer's detection
  • Research and development in neurodegenerative therapies
Growth Outlook
  • Simufilam has completed Phase 2b clinical evaluation, showing promise
  • Increasing focus on Alzheimer's disease, a growing healthcare concern
  • Potential for partnerships to enhance research and development capabilities
Financial Highlights
  • Market capitalization stands at approximately $1.45 million
  • Stock price has fluctuated between $0.02 and $11.02 in the past year
  • Recent trading volume reached over 2.5 million shares
Cassava Sciences, Inc. operates in the biotechnology sector, with a commitment to addressing significant health challenges associated with neurodegenerative diseases. The company's lead product, simufilam, has shown potential in clinical trials, positioning it as a key player in the Alzheimer's treatment landscape. The development of SavaDx further enhances its portfolio, providing a diagnostic tool that could revolutionize early detection methods. With a market capitalization of approximately $1.45 million and a notable trading volume, Cassava Sciences is attracting attention in the biotechnology field. The stock's price range over the past year indicates significant volatility, reflecting investor interest and market dynamics. Overall, Cassava Sciences, Inc. presents a compelling opportunity for those interested in the biotechnology sector focused on neurodegenerative disorders.
AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Austin, TX 78731, US

SAVAW Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Cassava Sciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABEOAbeona Therapeutics Inc.
$7.24+4.93%
ANVSAnnovis Bio, Inc.
$1.88+1.08%
AVXLAnavex Life Sciences Corp.
$3.34+1.83%
AXSMAxsome Therapeutics, Inc.
$212.74+1.24%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About SAVAW

What is the current price of Cassava Sciences?

Cassava Sciences is trading at N/A per share.

What is the 52-week range for Cassava Sciences?

Over the past 52 weeks, Cassava Sciences has traded between N/A and N/A.

How much debt does Cassava Sciences have?

Cassava Sciences total debt is unavailable.

How much cash does Cassava Sciences have on hand?

Cassava Sciences does not have cash on hand data available.

What is Cassava Sciences’s dividend yield?

Cassava Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services